

DEC 07 2000

-- ABSTRACT OF THE DISCLOSURE

TECH CENTER 1600/2900

B2
High energy phototherapeutic agents or radiosensitizer agents comprised of a halogenated xanthene, or other related agents that exhibit a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using such radiosensitizer agents in such diseased tissue are described herein.--

IN THE CLAIMS:

Please amend the claims as follows:

Sub-C2
B3
~~1 (Amended). A radiosensitizer agent for treatment of cancer and tumors [diseased tissue] using radiosensitization or ionizing radiation, said radiosensitizer agent comprising[:] a halogenated xanthene.~~

2 (Amended). The radiosensitizer agent of Claim 1, wherein said halogenated xanthene [is selected from the group comprising] comprises Rose Bengal [and its derivatives].

3 (Amended). The radiosensitizer agent of Claim 1, wherein said halogenated xanthene [is selected from the group comprising] comprises 4,5,6,7-Tetrabromoerythrosin [and its derivatives].

Sub-C3
~~4 (Amended). The radiosensitizer agent of Claim 1 wherein said halogenated xanthene includes as a functional derivative a targeting moiety selected from the group [comprising] consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors or complexing agents, lipid receptors or complexing agents, protein~~